Novartis acquires Enablex from Pfizer

Novartis (NVS; SWX:NOVN) will pay Pfizer (PFE) up to $225 million for Enablex darifenacin M3 antagonist to treat incontinence. Part of the payment is contingent on U.S. and EU approvals. NVS expects t...